

- Tenofovir has become a firmly established anti-retroviral in international guidelines and clinical practice since licensing in 2001.
- The clinical data is reviewed on the efficacy and tolerability of this HIV nucleotide reverse transcriptase inhibitor.
- There have been many pivotal studies that have utilized tenofovir, and we have over 7.5 million patient-years of global experience.
- Though it is well tolerated, low rates of significant renal toxicity are well recognized, and there are still questions around potential impacts on bone mineral density.
- Tenofovir alafenamide is likely to partially supersede tenofovir disoproxil fumarate in forthcoming years.

This summary slide represents the opinions of the authors. No funding or sponsorship was received for this study or publication of this article. For a full list of acknowledgments and conflicts of interest for all authors of this article, please see the full text online. Copyright © The Author(s) 2015. Creative Commons Attribution Noncommercial License (CC BY-NC).